Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

NCT03863184 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Acalabrutinib
DRUG: Lenalidomide
DRUG: Rituximab
DRUG: Obinutuzumab

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]
[object Object]